Filing Details

Accession Number:
0001127602-24-023162
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-29 16:45:44
Reporting Period:
2024-08-27
Accepted Time:
2024-08-29 16:45:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA Biological Products, (No Disgnostic Substances) (2836) 813467528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1736359 M James Mock 325 Binney Street
Cambridge MA 02142
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-27 1,326 $0.00 8,595 No 4 M Direct
Common Stock Acquisiton 2024-08-27 1,326 $0.00 9,921 No 4 M Direct
Common Stock Disposition 2024-08-28 1,321 $79.39 8,600 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Stock Units Disposition 2024-08-27 1,326 $0.00 1,326 $0.00
Common Stock Restricted Stock Units Disposition 2024-08-27 1,326 $0.00 1,326 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,652 No 4 M Direct
2,652 No 4 M Direct
Footnotes
  1. Performance stock units convert into common stock on a one-for-one basis.
  2. Restricted stock units convert into common stock on a one-for-one basis.
  3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of performance stock units and restricted stock units. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person.
  4. 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025.
  5. 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.